ArticleJAMA oncology2022
Systemic Anticancer Therapy at the End of Life-Changes in Usage Pattern in the Immunotherapy Era.
Article in JAMA oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- PALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of life.Palliative medicine · 2024Trial
- National trends in infection-related mortality among US cancer decedents in the immunotherapy era (1999-2023).Medicine · 2026Article
- Cancer care at the end of life: system-wide expenditure in a national health service.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Systemic anticancer therapy during end of life in head and neck squamous cell carcinoma patients. A retrospective single center study.Journal of cancer research and clinical oncology · 2025Observational
- Trend and Provider- and Organizational-Level Factors Associated With Early Palliative Care Billing Among Patients Diagnosed With Distant-Stage Cancers in 2010-2019 in the United States.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Systemic anticancer therapy at the end of life: real-world insights from a tertiary oncology center in Israel.The oncologist · 2025Article
- Review
- Novel Systemic Anticancer Therapy and Healthcare Utilization at the End of Life: A Retrospective Cohort Study.Cancer medicine · 2024Article
- Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors.JAMA oncology · 2024Article
- Anticancer therapy at end-of-life: A retrospective cohort study.Acta oncologica (Stockholm, Sweden) · 2024Article
- Illness trajectories of incurable solid cancers.BMJ (Clinical research ed.) · 2024Article
- End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Systemic Anticancer Treatment Near the End of Life: a Narrative Literature Review.Current treatment options in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.